Literature DB >> 2772099

The continuous performance test, identical pairs version: II. Contrasting attentional profiles in schizophrenic and depressed patients.

B A Cornblatt1, M F Lenzenweger, L Erlenmeyer-Kimling.   

Abstract

The Continuous Performance Test-Identical Pairs version was administered to 14 schizophrenic patients, 17 depressed patients, and 28 normal controls. The task was divided into verbal and spatial stimuli, as well as no-distraction and distraction (verbal and auditory) conditions. Both patient groups displayed attentional impairments compared to normal subjects, but they differed from each other in specific profiles. Schizophrenic patients were characterized by a global impairment and a particular inability to focus on the critical stimuli, whether verbal or spatial. They also made an excess of random responses throughout the task but showed no evidence that attention declined from its initial level over time. Depressed patients did not display a global attentional deficit but did show a specific inability to attend to spatial as compared to verbal stimuli and, in particular, a confusion when the spatial stimuli were only slightly different. Performance on a secondary task in response to a change in expectation improved dramatically for depressed but not schizophrenic patients, suggesting a more efficient allocation strategy, a greater reserve of processing capacity, or more dependence on motivational factors in depressed patients. Schizophrenic and depressed patients were alike in extent of distractibility. Whereas normal controls improved with the onset of external distraction, schizophrenic and depressed patients deteriorated to an equal extent. Distractibility was thus concluded to be a correlate of acute psychiatric illness and not specific for schizophrenia.

Entities:  

Mesh:

Year:  1989        PMID: 2772099     DOI: 10.1016/0165-1781(89)90188-1

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  67 in total

1.  Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study.

Authors:  Philip D Harvey; Michael F Green; Susan R McGurk; Herbert Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2003-02-18       Impact factor: 4.530

2.  The European Prediction of Psychosis Study (EPOS): integrating early recognition and intervention in Europe.

Authors:  Joachim Klosterkötter; Stephan Ruhrmann; Frauke Schultze-Lutter; Raimo K R Salokangas; Don Linszen; Max Birchwood; Georg Juckel; Anthony Morrison; José Luis Vázquèz-Barquero; Martin Hambrecht; Heinrich VON Reventlow
Journal:  World Psychiatry       Date:  2005-10       Impact factor: 49.548

Review 3.  Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes.

Authors:  Beth E Snitz; Angus W Macdonald; Cameron S Carter
Journal:  Schizophr Bull       Date:  2005-09-15       Impact factor: 9.306

4.  Premorbid characterization in schizophrenia: the Pittsburgh High Risk Study.

Authors:  Matcheri S Keshavan; Vaibhav A Diwadkar; Debra M Montrose; Jeff A Stanley; Jay W Pettegrew
Journal:  World Psychiatry       Date:  2004-10       Impact factor: 49.548

5.  Hypo-activation in the executive core of the sustained attention network in adolescent offspring of schizophrenia patients mediated by premorbid functional deficits.

Authors:  Vaibhav A Diwadkar; Jamie Segel; Patrick Pruitt; Eric R Murphy; Matcheri S Keshavan; Jacqueline Radwan; Usha Rajan; Caroline Zajac-Benitez
Journal:  Psychiatry Res       Date:  2011-04-15       Impact factor: 3.222

6.  Dissociation of acute and chronic intermittent phencyclidine-induced performance deficits in the 5-choice serial reaction time task: influence of clozapine.

Authors:  David M Thomson; Allan McVie; Brian J Morris; Judith A Pratt
Journal:  Psychopharmacology (Berl)       Date:  2010-09-29       Impact factor: 4.530

Review 7.  Antipsychotic medication for elderly people with schizophrenia.

Authors:  R G Marriott; W Neil; S Waddingham
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

8.  Subjective and objective quality of life in schizophrenia.

Authors:  Jenille M Narvaez; Elizabeth W Twamley; Christine L McKibbin; Robert K Heaton; Thomas L Patterson
Journal:  Schizophr Res       Date:  2007-10-04       Impact factor: 4.939

Review 9.  Endophenotypes in schizophrenia: a selective review.

Authors:  Allyssa J Allen; Mélina E Griss; Bradley S Folley; Keith A Hawkins; Godfrey D Pearlson
Journal:  Schizophr Res       Date:  2009-02-15       Impact factor: 4.939

10.  Attenuation of d-amphetamine-induced disruption of conditional discrimination performance by alpha-flupenthixol.

Authors:  Michael J Dunn; David Futter; Charlotte Bonardi; Simon Killcross
Journal:  Psychopharmacology (Berl)       Date:  2004-09-24       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.